Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1484-1490

  Tiwari, Arun K ^a   Rodgers, Jarlath B ^a   Sicard, Michelle ^a   Zai, Clement C ^a   Likhodi, Olga ^a   Freeman, Natalie ^a   Meltzer, Herbert Y ^b   Lieberman, Jeffrey A ^c   Kennedy, James L ^a   Müller, Daniel J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Psychiatric Hospital at Vanderbilt   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Association; CCK; CCKB; Clozapine; Olanzapine; Weight gain

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT CHANGE; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHOLECYSTOKININ; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; SCHIZOPHRENIA; WEIGHT GAIN; YOUNG ADULT;

EID: 78649505049     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.009     Document Type: Article

References (46)

1. Allison D.B., Mackell J.A., McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003, 54:565-567.
2. Aronne L.J. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001, 62(Suppl 23):13-22.
3. Barden N., Merand Y., Rouleau D., Moore S., Dockray G.J., Dupont A. Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain. Peptides 1981, 2:299-302.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Basile V.S., Masellis M., De Luca V., Meltzer H.Y., Kennedy J.L. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360:1790-1791.
6. Beinfeld M.C., Meyer D.K., Eskay R.L., Jensen R.T., Brownstein M.J. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981, 212:51-57.
7. Bowen T., Norton N., Jacobsen N.J., Guy C., Daniels J.K., Sanders R.D., et al. Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. Mol Psychiatry 1998, 3:67-71.
8. Buffa R., Solcia E., Go V.L. Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa. Gastroenterology 1976, 70:528-532.
9. Chandra R., Liddle R.A. Cholecystokinin. Curr Opin Endocrinol Diab Obes 2007, 14:63-67.
10. Crisp A.H., Gelder M.G., Rix S., Meltzer H.I., Rowlands O.J. Stigmatisation of people with mental illnesses. Br J Psychiatry 2000, 177:4-7.
11. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007, 10:697-704.
12. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121.
13. Dufresne M., Seva C., Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006, 86:805-847.
14. Ellingrod V.L., Perry P.J., Ringold J.C., Lund B.C., Bever-Stille K., Fleming F., et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:76-78.
15. Gauderman W.J., Morrison J.M. A computer program for power and sample size calculations for genetic-epidemiology studies http://hydra.usc.edu/gxe.
16. Gibbs J., Young R.C., Smith G.P. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 1973, 245:323-325.
17. Girgis R.R., Javitch J.A., Lieberman J.A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008, 13:918-929.
18. Hamilton S.P., Slager S.L., Helleby L., Heiman G.A., Klein D.F., Hodge S.E., et al. No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiatry 2001, 6:59-65.
19. Hattori E., Ebihara M., Yamada K., Ohba H., Shibuya H., Yoshikawa T. Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. Mol Psychiatry 2001, 6:465-470.
20. Hosing V.G., Schirmacher A., Kuhlenbaumer G., Freitag C., Sand P., Schlesiger C., et al. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl 2004, 147-156.
21. Hutchison K.E., Haughey H., Niculescu M., Schacht J., Kaiser A., Stitzel J., et al. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 2008, 65:841-850.
22. Kennedy J.L., Bradwejn J., Koszycki D., King N., Crowe R., Vincent J., et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 1999, 4:284-285.
23. Kissileff H.R., Pi-Sunyer F.X., Thornton J., Smith G.P. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981, 34:154-160.
24. Kopin A.S., Mathes W.F., McBride E.W., Nguyen M., Al-Haider W., Schmitz F., et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999, 103:383-391.
25. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19:5444.
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
27. Lin P.I., Vance J.M., Pericak-Vance M.A., Martin E.R. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007, 80:531-538.
28. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19:123-132.
29. Melville L.D., Smith G.P., Gibbs J. Devazepide antagonizes the inhibitory effect of cholecystokinin on intake in sham-feeding rats. Pharmacol Biochem Behav 1992, 43:975-977.
30. Miller D.D., Ellingrod V.L., Holman T.L., Buckley P.F., Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 133B:97-100.
31. Moran T.H., Katz L.F., Plata-Salaman C.R., Schwartz G.J. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 1998, 274:R618-R625.
32. Müller D.J., Kennedy J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7:863-887.
33. Müller D.J., De Luca V., Sicard T., King N., Hwang R., Volavka J., et al. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005, 15:525-531.
34. Müller D.J., Klempan T.A., De Luca V., Sicard T., Volavka J., Czobor P., et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005, 379:81-89.
35. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
36. Neary M.T., Batterham R.L. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009, 124:44-56.
37. Reynolds G.P., Templeman L.A., Zhang Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1021-1028.
38. Tachikawa H., Harada S., Kawanishi Y., Okubo T., Shiraishi H. Novel polymorphism in the promoter and coding regions of the human cholecystokinin B receptor gene: an association analysis with schizophrenia. Am J Med Genet 1999, 88:700-704.
39. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200.
40. Tiwari A.K., Zai C.C., Likhodi O., Lisker A., Singh D., Souza R.P., et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010, 35:1315-1324.
41. Tiwari A.K., Zai C.C., Meltzer H.Y., Lieberman J.A., Müller D.J., Kennedy J.L. Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol 2010, 25:253-259.
42. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002, 159:255-262.
43. Wank S.A. Cholecystokinin receptors. Am J Physiol 1995, 269:G628-G646.
44. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004, 65(Suppl 18):13-26.
45. Zaykin D.V., Shibata K. Genetic flip-flop without an accompanying change in linkage disequilibrium. Am J Hum Genet 2008, 82:794-796. [author reply 6-7].
46. Zhang Z.J., Yao Z.J., Mou X.D., Chen J.F., Zhu R.X., Liu W., et al. Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Zhonghua Yi Xue Za Zhi 2003, 83:2119-2123.